<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01391338</url>
  </required_header>
  <id_info>
    <org_study_id>3652-CL-0019</org_study_id>
    <secondary_id>2010-023775-25</secondary_id>
    <nct_id>NCT01391338</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)</brief_title>
  <acronym>AZURE</acronym>
  <official_title>A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of CP/CPPS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study several doses of ASP3652, given orally for 12 weeks, will be compared with
      placebo in the treatment of patients with Chronic abacterial Prostatitis / Chronic Pelvic
      Pain Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate the efficacy of ASP3652 in the treatment of patients with Chronic
      abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS). In comparison with placebo,
      ASP3652 will be given in different dosages orally for 12 weeks. The aims are to investigate
      efficacy of ASP3652 in CP/CPPS, to assess the optimal dose of ASP3652, to investigate safety
      and tolerability and to investigate pharmacokinetics and pharmacodynamics of ASP3652 in
      patients with CP/CPPS in and out-patients setting.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI), total score at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the NIH-CPSI pain domain score at week 12</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NIH-CPSI total score at 4 and 8 weeks and at 2 weeks follow-up after treatment</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks and 2 weeks follow-up post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NIH-CPSI pain domain at week 4 and 8 and at 2 weeks follow-up after treatment</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks 2 weeks follow-up post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NIH-CPSI urinary symptoms domain at week 4, 8 and 12 and at 2 weeks follow-up after treatment</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks and 12 weeks treatment and weeks 2 weeks follow-up post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NIH-CPSI Quality of Life impact domain at week 4, 8 and 12 and at 2 weeks follow-up after treatment</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks and 12 weeks treatment and weeks 2 weeks follow-up post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Response Assessment at week 4, 8 and 12 and at 2 weeks follow-up post treatment</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks and 12 weeks treatment and at 2 weeks follow-up post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of Clinical Responders</measure>
    <time_frame>12 weeks</time_frame>
    <description>Composite of two definitions are used: subjects who showed at least 4 points decrease in NIH-CPSI total score at 12 weeks compared to baseline and subjects who showed at least 6 points decrease in NIH-CPSI total score at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genitourinary pain index (GUPI) total score, sub domain and responders, at week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Responder defined as 7 points or more decrease from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean daily CPSI-24hour total score at baseline and at 4, 8 and 12 weeks and 2 weeks follow-up post treatment</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks and 12 weeks and 2 weeks follow-up post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean daily pain for the 7 days period prior to attending study visits at baseline and at 4, 8 and 12 weeks and 2 weeks follow-up post treatment</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks and 12 weeks and 2 weeks follow-up post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short form McGill pain questionnaire: sensory, affective and total score, VAS, present pain intensity at baseline and at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voiding: mean number of micturitions per 24 hours and per night, mean number of urgency episodes per 24 hours and mean level of urgency per micturition</measure>
    <time_frame>Baseline, 4 weeks and 12 weeks treatment</time_frame>
    <description>Based on daily urinary symptom diary for 3 consecutive days in the weeks prior to the visits at baseline, 4 and 12 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score at screening and at 12 weeks</measure>
    <time_frame>Screening and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Quality of Life questionnaire in 5 dimensions (EQ-5D) at baseline and at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Male sexual health questionnaire at baseline and at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">239</enrollment>
  <condition>Chronic Abacterial Prostatitis</condition>
  <condition>Chronic Pelvic Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Lowest dose ASP3652 twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose ASP3652 twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose ASP3652 twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose ASP3652 once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose ASP3652 twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP3652</intervention_name>
    <description>Oral</description>
    <arm_group_label>Lowest dose ASP3652 twice daily</arm_group_label>
    <arm_group_label>Low dose ASP3652 twice daily</arm_group_label>
    <arm_group_label>Medium dose ASP3652 twice daily</arm_group_label>
    <arm_group_label>High dose ASP3652 once daily</arm_group_label>
    <arm_group_label>High dose ASP3652 twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is diagnosed with CP/CPPS with symptoms for at least 3 months over the last 6 months

          -  Has a NIH-CPSI total score of at least 15

          -  A score of at least 4 on question 4 (pain) in the NIH-CPSI

          -  Reports pain on palpation of the prostate or the perineum/genital area

          -  Answers &quot;yes&quot; to at least 1 out of 6 items in question 1 and 2 of the NIH-CPSI

          -  Is willing to comply with study requirements such as completing the micturition and
             symptoms diary and attend all study visits

        Exclusion Criteria:

          -  Isolated unilateral testicular, penile or scrotal pain as a solitary symptom of pelvic
             pain

          -  Urinary Tract Infection (UTI) or prostate infection found at screening using the pre-
             and post massage test or in the last 3 months prior to screening

          -  Any prior prostate and or bladder intervention within 3 months prior to screening

          -  Lower urinary tract malignancy (suspected), such as positive (micro) hematuria in
             urine sediment or Prostate Specific Antigen (PSA) &gt;4 ng/mL

          -  Symptomatic urethral stricture or symptomatic bladder or urethral calculi, severe
             bladder outlet obstruction, overactive bladder with incontinence or Post Void Residual
             volume, greater than 150 mL

          -  Clinically significant abnormalities on transabdominal ultrasound of bladder and
             prostate or neurological disease or defect affecting bladder function

          -  Currently active sexually transmittable disease

          -  Substance abuse or any use of delta-9-tetrahydrocannabinol (THC) as assessed by a
             positive urine test for THC at screening

          -  Major depression, i.e. a Center for Epidemiological Studies Depression Scale score of
             27 or more

          -  Any clinically relevant concomitant disease (past or present) which would, in the
             opinion of the investigator, put the subject at risk or mask measures of efficacy

          -  Use of steroids, immunomodulators, anticonvulsants, cytochrome P4502C8 inhibitors,
             cannabis/THC based medication, opioid analgetics or antiviral/antimicrobial/antifungal
             agents during the last 4 weeks before screening

          -  Initiation, discontinuation, or variation in the dose of antidepressants,
             alpha-blockers, 5-alpha reductase inhibitors, antimuscarinics, benzodiazepines,
             skeletal muscle relaxants, non-steroidal antiinflammatory drugs, non-opioid analgetics
             and herbal therapies during the last 4 weeks before screening. Subjects should
             continue these medications at that same stable dose throughout the study

          -  Clinically relevant abnormal urine or blood safety laboratory values or active hepatic
             and/or biliary disease (AST or ALT should not be &gt;3 times the upper limit of normal,
             total bilirubin should not be &gt;2 times the upper limit of normal)

          -  Participated in any clinical study or has been treated with any investigational drug
             or device within 30 days prior to screening, or the period stipulated by local
             regulations, whichever is longer
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Executive Director Global Medical Science</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Coordination Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic for Urology, Pediatric Urology and Andrology, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site: 3105 - Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3106 - Urologicke oddeleniUsti nad Labem</name>
      <address>
        <city>Kolin</city>
        <zip>28000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3109- Hospital Kromeriz</name>
      <address>
        <city>Kromeriz</city>
        <zip>76755</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3107 - Urologie</name>
      <address>
        <city>Novy Jicin</city>
        <zip>74101</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3103 - Fakultni nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>77200</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3111 - Urology center</name>
      <address>
        <city>Plzen</city>
        <zip>30100</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3102 - Androgeos</name>
      <address>
        <city>Praha 6</city>
        <zip>16000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3112 - Urosante</name>
      <address>
        <city>Praha</city>
        <zip>14000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3110 - Urologicka ordinace</name>
      <address>
        <city>Sternberk</city>
        <zip>78501</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3104 - Uherskohradistska nemocnice a.s.</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>68668</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3101- Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad Labem, o.z.</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>40113</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3113 - Urologicka ambulance</name>
      <address>
        <city>Zatec</city>
        <zip>43801</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3212 - Urologische Praxis</name>
      <address>
        <city>Berlin</city>
        <zip>10719</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3214 - Charité Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3208 - Private Praxis Urologie Borken</name>
      <address>
        <city>Borken</city>
        <zip>46325</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3202 - Urologische Praxis</name>
      <address>
        <city>Buchholz</city>
        <zip>21244</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3201 - Universitats klinikum Giessen und Marburg</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3203 - Urologische Praxis</name>
      <address>
        <city>Hamburg</city>
        <zip>22587</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3211 - Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Herzogenaurach</city>
        <zip>91074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3205 - Gesundheitszentrum Holzminden</name>
      <address>
        <city>Holzminden</city>
        <zip>37603</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3213 - Urologische Praxis</name>
      <address>
        <city>Kempen</city>
        <zip>47906</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3206 - Private Praxis</name>
      <address>
        <city>Leipzig</city>
        <zip>04179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3210 - Private Praxis</name>
      <address>
        <city>Marburg</city>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3207 - Private Praxis</name>
      <address>
        <city>Markkleeberg</city>
        <zip>04416</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3204 - Akademisches Lehrkrankenhaus</name>
      <address>
        <city>Neunkirchen</city>
        <zip>66538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3215 - Urologische Praxis</name>
      <address>
        <city>Reutlingen</city>
        <zip>72764</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3209 - Private Praxis</name>
      <address>
        <city>Sangerhausen</city>
        <zip>06526</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3302 - Jelgava Outpatient Clinic</name>
      <address>
        <city>Jelgava</city>
        <zip>LV-3001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3301 - Litavniece Urologist Private Practice</name>
      <address>
        <city>Liepaja</city>
        <zip>LV-3401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3303 - P. Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3304 - Nord Kurzeme Regional Hospital</name>
      <address>
        <city>Ventspils</city>
        <zip>LV-3601</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3404 - Motina ir vaikas clinic</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50154</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3402 - Vilnius Univeristy Hospital &quot;Santariskiu Klinikos&quot; Urology Centre</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3401 - Clinics &quot;Privatus gydytojas&quot;</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-09108</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3403 - Public Institution Vilnius City University Hospital</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-10207</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3503 - Urovita Sp.z.o.o. NZOZ Szpital Slaskie Centrum Urologii</name>
      <address>
        <city>Chorzow</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3504 - Centrum Medyczne Szpital Sw Rodziny Sp z o.o.</name>
      <address>
        <city>Lodz</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3509 - NZOZ Nasz Lekarz, Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna</name>
      <address>
        <city>Lotum</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3510 - Heureka Hanna Szalecka</name>
      <address>
        <city>Piaseczno</city>
        <zip>05-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3501 - Indywidualna Specjalistyczna Praktyka Lekarska</name>
      <address>
        <city>Poznan</city>
        <zip>61-397</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3511 - Urologica Praktyka Lekarska Adam Marcheluk</name>
      <address>
        <city>Siedlce</city>
        <zip>08-110</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3508 - NZOZ Centrum Medyczna Wola</name>
      <address>
        <city>Warszawa</city>
        <zip>01-432</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3507 - Szpital Kliniczny Dzieciatka Jezus Centrum Leczenia Obrazen</name>
      <address>
        <city>Warszawa</city>
        <zip>02-005</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3502 - Wojewodzki Szpital Specjalistyczny we Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3505 - EMC Instytut Medyczny SA</name>
      <address>
        <city>Wroclaw</city>
        <zip>54-144</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3506 - Specjalistyczna Praktyka Lekarska Gabinet Urologiczny</name>
      <address>
        <city>Wroclaw</city>
        <zip>54-239</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3701 - Hospital Moises Broggi de Sant Joa</name>
      <address>
        <city>Barcelona</city>
        <zip>8970</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3703 - Fundació Puigvert</name>
      <address>
        <city>Barcelona</city>
        <zip>CP: 08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 3702 - Hospital del Henares</name>
      <address>
        <city>Coslada</city>
        <zip>CP:28822</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2011</study_first_submitted>
  <study_first_submitted_qc>July 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2011</study_first_posted>
  <last_update_submitted>March 19, 2013</last_update_submitted>
  <last_update_submitted_qc>March 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostatitis</keyword>
  <keyword>Chronic</keyword>
  <keyword>Pelvic Pain</keyword>
  <keyword>NIH-CPSI</keyword>
  <keyword>Pain domain score in NIH-CPSI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
    <mesh_term>Prostatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

